Delving into the Latest Updates on AstraZeneca Nijmegen BV with Synapse

Overview

Tags

Skin and Musculoskeletal Diseases

Urogenital Diseases

Neoplasms

Monoclonal antibody

Bispecific antibody

CAR-TILs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	5
Nervous System Diseases	2
Infectious Diseases	2
Immune System Diseases	2
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Monoclonal antibody	4
Bispecific antibody	2
CAR-TILs	1

Top 5 Target	Count

CD73(5-nucleotidase)	1
PD-1 x TIGIT	1
IFNAR-1(Interferon-alpha/beta receptor alpha chain)	1
NKG2A(killer cell lectin like receptor C1)	1
CD19(B-lymphocyte antigen CD19)	1

[Translation] A two-arm, parallel, randomized, multicenter, open-label, global Phase III study to determine the efficacy of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy as first-line treatment for patients with metastatic non-small cell lung cancer (mNSCLC) (eVOLVE-Lung02)

本研究主要目的是：（a）通过评估PD-L1 TC < 1%参与者的无进展生存期（PFS）（BICR根据RECIST 1.1评估），证明volrustomig + 化疗相较于帕博利珠单抗 + 化疗的疗效。（b）通过评估PD-L1 TC < 1%参与者的总生存期（OS），证明volrustomig + 化疗相较于帕博利珠单抗 + 化疗的疗效。

[Translation]

The primary objectives of this study are to: (a) demonstrate the efficacy of volrustomig + chemotherapy compared with pembrolizumab + chemotherapy by evaluating progression-free survival (PFS) in participants with PD-L1 TC < 1% (BICR according to RECIST 1.1) and (b) demonstrate the efficacy of volrustomig + chemotherapy compared with pembrolizumab + chemotherapy by evaluating overall survival (OS) in participants with PD-L1 TC < 1%.

Start Date19 Mar 2025

Sponsor / Collaborator

AstraZeneca Global R&D (China) Co., Ltd.

[+2]

CTR20250005

/ RecruitingPhase 1

一项评价AZD5492（一种靶向CD20的T细胞结合抗体）在复发性或难治性B细胞恶性肿瘤受试者中安全性、药代动力学、药效学和有效性的开放标签、剂量递增和剂量扩展的模块化I/II期研究（TITANium）

[Translation] An open-label, dose-escalation and dose-expansion modular phase I/II study evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of AZD5492, a CD20-targeted T-cell engaging antibody, in subjects with relapsed or refractory B-cell malignancies (TITANium)

评估AZD5492单药治疗或与其他抗癌药物联合治疗R/R B细胞恶性肿瘤受试者的安全性和耐受性

[Translation]

To evaluate the safety and tolerability of AZD5492 as monotherapy or in combination with other anticancer drugs in subjects with R/R B-cell malignancies

Start Date19 Mar 2025

Sponsor / Collaborator

AstraZeneca Global R&D (China) Co., Ltd.

[+2]

100 Clinical Results associated with AstraZeneca Nijmegen BV

Login to view more data

0 Patents (Medical) associated with AstraZeneca Nijmegen BV

Login to view more data

100 Deals associated with AstraZeneca Nijmegen BV

Login to view more data

100 Translational Medicine associated with AstraZeneca Nijmegen BV

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 12 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

4

Phase 3 Clinical

NDA/BLA

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Inebilizumab-cdon ( CD19 )	-	NDA/BLA
Monalizumab ( NKG2A )	Locally Advanced Lung Non-Small Cell Carcinoma More	Phase 3
Oleclumab ( CD73 )	Locally Advanced Lung Non-Small Cell Carcinoma More	Phase 3
Rilvegostomig ( PD-1 x TIGIT )	HER2-positive gastric cancer More	Phase 3
Anifrolumab-FNIA ( IFNAR-1 )	Lupus Nephritis More	Phase 3